Kohlberg Kravis Roberts & Co. L.P. BBIO — BRIDGEBIO PHARMA INC

Ownership history in Kohlberg Kravis Roberts & Co. L.P.  ·  28 quarters on record

AI Ownership Summary

Kohlberg Kravis Roberts & Co. L.P. reported BRIDGEBIO PHARMA INC (BBIO) in 28 quarterly 13F filings from 2023 Q4 through 2026 Q1. Peak portfolio weight reached 37.06% in 2023 Q4. The latest visible filing shows BBIO at 18.42% of the fund.

This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings. Older history is available after unlock; the visible window still shows the most recent pattern.

What this BBIO ownership page tells you

This page is designed to answer the real investor question behind a 13F filing: how meaningful was Kohlberg Kravis Roberts & Co. L.P.'s position in BRIDGEBIO PHARMA INC, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.

Freshest filing
Latest Reported Filing
2026 Q1

BBIO was reported at 18.42% of portfolio in the most recent visible filing.

High-water mark
Peak Conviction
37.06% in 2023 Q4

Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.

Time in book
Holding Window
2023 Q4 to 2026 Q1

Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.

Decision context
Why It Matters
Position size beats headlines

Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.

BBIO stock page Kohlberg Kravis Roberts & Co. L.P. fund profile Kohlberg Kravis Roberts & Co. L.P. full holdings
How Kohlberg Kravis Roberts & Co. L.P. held BBIO — position size vs. price
% of Fund (quarterly)    BBIO price (quarter-end, indexed to 100)    SPY (indexed to 100)    QQQ (indexed to 100)
📋 Quarterly Holdings History 10 quarters  ▾
Quarter Action Sold % After 3M Timing Shares Change Chg % % of Fund Mkt Value Filed Price (Filed)
2026 Q1 UNCHANGED — — — 13,260,971 — 0% 18.42% $984.8M 2026-05-15 $66.13
2025 Q4 UNCHANGED — — — 13,260,971 — 0% 16.22% $1.01B 2026-02-17 $75.85
2025 Q3 UNCHANGED — — — 13,260,971 — 0% 11.54% $688.77B 2025-11-14 $66.39
2025 Q2 REDUCED 31.2% +20.3% ❌ 13,260,971 -6,000,000 -31.2% 11.83% $572.61B 2025-08-14 $51.18
2025 Q1 REDUCED 23.8% +24.9% ❌ 19,260,971 -6,000,000 -23.8% 15.04% $665.85B 2025-05-15 $33.74
2024 Q4 UNCHANGED — — — 25,260,971 — 0% 18.56% $693.16B 2025-02-14 $34.90
2024 Q3 REDUCED 18.7% +7.3% ❌ 25,260,971 -5,800,000 -18.7% 8.61% $643.14B 2024-11-14 $24.11
2024 Q2 UNCHANGED — — — 31,060,971 — 0% 23.60% $786.77B 2024-08-14 $24.25
2024 Q1 UNCHANGED — — — 31,060,971 — 0% 24.77% $960.41B 2024-05-15 $29.97
2023 Q4 UNCHANGED — — — 31,060,971 — 0% 37.06% $1253.93B 2024-02-14 $34.37
18 older quarters hidden  —  Sign in free or upgrade to Premium to see full history

🏢 Other funds also holding BBIO

As of 2026 Q1 — sorted by position size

Aisling Capital Management LP 3Y 7Y 79.35% Catalio Capital Management, LP 6.7% Frazier Life Sciences Management, L.P. 3Y 6.59% First Turn Management, LLC 5.77% BOONE CAPITAL MANAGEMENT LLC 3Y 5.21% Laurion Capital Management LP 3Y 7Y 4.09% Knott David M Jr 3Y 3.98% FARALLON CAPITAL MANAGEMENT LLC 3Y 7Y 3.96% Atle Fund Management AB 3Y 7Y 3.84% Eagle Health Investments LP 3Y 3.47%

FAQ About Kohlberg Kravis Roberts & Co. L.P. and BBIO

These are the practical questions this page is built to answer before you even open the full history table.

How long has Kohlberg Kravis Roberts & Co. L.P. reported owning BBIO?

Kohlberg Kravis Roberts & Co. L.P. reported BBIO across 10 quarterly 13F filings, from 2023 Q4 through 2026 Q1.

What was the largest reported BBIO position in Kohlberg Kravis Roberts & Co. L.P.'s portfolio?

The largest reported portfolio weight for BBIO was 37.06% in 2023 Q4.

What is the latest reported BBIO position on this page?

The most recent filing on this page is 2026 Q1, when Kohlberg Kravis Roberts & Co. L.P. reported 13,260,971 shares, equal to 18.42% of portfolio, with an estimated market value of $984.8M.

What does the chart on this BBIO ownership page compare?

The chart compares Kohlberg Kravis Roberts & Co. L.P.'s quarterly BBIO portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.

How well did Kohlberg Kravis Roberts & Co. L.P. time their BBIO position?

Based on 13F filing dates vs. subsequent BBIO price moves, Kohlberg Kravis Roberts & Co. L.P. correctly timed 2 out of 6 reported position changes (33%). The annualised alpha on BBIO relative to SPY over the holding period was +0.0%.

← Back to Kohlberg Kravis Roberts & Co. L.P. Holdings